Company profile
Oncolytics Biotech Inc.
NASDAQ: ONCY · Healthcare · Biotechnology
Canadian filerHQ Calgary, ABCIK 0001129928Reports USD
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH 13DQ —GM —SS 63
v0.1 · 35/100 weight · pillars only
↑ listing tenure, market scale · ↓ Piotroski F, return on assets
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$28.8M
Employees
29
as of 2026-08-18
Market cap
$85.8M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$28.8M-$28.8M2025
Operating income-$28.7M-$28.7M2025
Total assets$7.6M$7.6M2025
Liabilities$11.4M$11.4M2025
Equity-$3.8M-$3.8M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Oncolytics Biotech Inc.’s financial profile?
Oncolytics Biotech Inc. earned -$28.8M in FY2025 net income.
Peers · Healthcare
Acrivon Therapeutics, Inc. Common Stock——NDT Pharmaceuticals Inc.——Aldeyra The——Adicet Bio, Inc.——Dogwood Therapeutics, Inc.——Telomir Pharmaceuticals, Inc. Common Stock——Key facts
CEOJared Kelly
SectorHealthcare
IndustryBiotechnology
HeadquartersCalgary, AB
ExchangeNASDAQ: ONCY
Employees29
IPO date2001-10-05
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.